Dr Reddys Laboratories Stock Screener | Share Price & Fundamental Analysis
DRREDDY
Pharmaceuticals
Screen Dr Reddys Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1250.00
▼
-6.10 (-0.49%)
Share Price BSE
₹1248.75
▼
-6.70 (-0.53%)
Market Cap
₹104,570.84 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.95
EPS (TTM)
₹67.89
Dividend Yield
0.63%
Debt to Equity
0.11
52W High
₹1371.60
52W Low
₹1087.90
Operating Margin
23.00%
Profit Margin
14.64%
Revenue (TTM)
₹9,135.00
EBITDA
₹2,317.00
Net Income
₹1,337.00
Total Assets
₹49,427.00
Total Equity
₹33,927.00
Dr Reddys Laboratories Share Price History - Stock Screener Chart
Screen DRREDDY historical share price movements with interactive charts. Analyze price trends and patterns.
Dr Reddys Laboratories Company Profile - Fundamental Screener
Screen Dr Reddys Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DRREDDY shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE089A01031
Dr Reddys Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen DRREDDY balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 49,427 | 38,864 | 32,285 | 29,747 | 26,617 | 23,225 | 22,466 | 22,544 | 21,817 | 20,384 |
| Current Assets | 25,018 | 24,805 | 20,426 | 17,782 | 14,550 | 12,599 | 11,110 | 10,498 | 9,684 | 11,794 |
| Fixed Assets | 18,226 | 10,426 | 9,219 | 8,122 | 8,206 | 6,850 | 7,191 | 6,968 | 6,931 | 6,563 |
| Liabilities | ||||||||||
| Total Liabilities | 49,427 | 38,864 | 32,285 | 29,747 | 26,617 | 23,225 | 22,466 | 22,544 | 21,817 | 20,384 |
| Current Liabilities | 2,465 | 1,021 | 427 | 769 | 871 | 412 | 2,545 | 3,079 | 1,135 | 1,467 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 33,927 | 28,255 | 23,286 | 19,212 | 17,642 | 15,599 | 14,024 | 12,572 | 12,262 | 12,570 |
| Share Capital | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 85 |
| Reserves & Surplus | 33,466 | 28,171 | 23,330 | 19,289 | 17,755 | 15,616 | 13,994 | 12,489 | 12,179 | 12,485 |
Screen DRREDDY income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,135 | 8,836 | 9,034 | 8,513 | 8,330 | 7,866 | 7,284 | 7,434 | 7,199 | 6,917 | 6,443 | 6,835 | 6,361 | 6,079 | 5,569 |
| Expenses | 6,818 | 6,399 | 6,531 | 6,108 | 5,962 | 5,566 | 5,283 | 5,214 | 4,894 | 4,696 | 4,781 | 4,851 | 4,433 | 4,292 | 5,024 |
| EBITDA | 2,317 | 2,437 | 2,503 | 2,405 | 2,368 | 2,300 | 2,001 | 2,220 | 2,305 | 2,221 | 1,662 | 1,983 | 1,928 | 1,787 | 545 |
| Operating Profit % | 23.00% | 25.00% | 23.00% | 27.00% | 26.00% | 27.00% | 25.00% | 28.00% | 29.00% | 30.00% | 24.00% | 28.00% | 30.00% | 18.00% | 8.00% |
| Depreciation | 505 | 476 | 455 | 471 | 397 | 381 | 368 | 374 | 376 | 353 | 316 | 324 | 309 | 302 | 293 |
| Interest | 91 | 83 | 66 | 82 | 76 | 60 | 59 | 39 | 35 | 37 | 35 | 42 | 31 | 35 | 32 |
| Profit Before Tax | 1,745 | 1,905 | 2,005 | 1,874 | 1,917 | 1,883 | 1,605 | 1,829 | 1,917 | 1,850 | 1,329 | 1,638 | 1,614 | 1,468 | 259 |
| Tax | 408 | 495 | 419 | 470 | 576 | 490 | 295 | 448 | 435 | 445 | 369 | 394 | 499 | 279 | 162 |
| Net Profit | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 | 1,392 | 1,310 | 1,381 | 1,482 | 1,405 | 960 | 1,244 | 1,114 | 1,189 | 97 |
| EPS | 16.18 | 17.04 | 19.12 | 16.97 | 75.40 | 83.61 | 78.66 | 82.94 | 89.09 | 84.55 | 57.79 | 74.91 | 67.13 | 71.64 | 5.84 |
Dr Reddys Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen DRREDDY cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 4,643 | 4,543 | 5,888 | 2,811 | 3,570 | 2,984 | 2,870 | 1,803 | 2,144 | 3,263 |
| Investing Activities | -5,785 | -4,034 | -4,109 | -2,565 | -2,255 | -495 | -769 | -1,483 | -1,890 | -1,610 |
| Financing Activities | 1,891 | -376 | -2,686 | -242 | -30 | -2,516 | -2,133 | -444 | -369 | -1,700 |
| Net Cash Flow | 749 | 133 | -907 | 3 | 1,286 | -27 | -31 | -124 | -114 | -47 |
Screen DRREDDY shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 26.64% | 26.64% | 26.64% | 26.65% | 26.65% | 26.64% | 26.64% | 26.70% |
| FII Holding | 37.29% | 36.36% | 35.52% | 44.49% | 42.27% | 41.75% | 40.08% | 0.00% |
| DII Holding | 25.62% | 26.74% | 27.98% | 18.31% | 20.73% | 21.48% | 22.90% | 23.05% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 8.20% | 8.04% | 7.56% | 8.25% | 8.07% | 8.07% | 8.07% | 7.59% |
| Other Holding | 2.25% | 2.22% | 2.30% | 2.30% | 2.29% | 2.06% | 2.30% | 42.66% |
| Shareholder Count | 459,605 | 451,929 | 449,216 | 255,500 | 267,694 | 310,403 | 403,669 | 232,715 |
Dr Reddys Laboratories Dividend Screener - Share Yield Analysis
Screen DRREDDY dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹8.00 | 0.63% |
| 2024-March | ₹40.00 | 3.50% |
| 2023-March | ₹40.00 | 3.25% |
| 2022-March | ₹30.00 | 3.24% |
| 2021-March | ₹25.00 | 2.91% |
| 2020-March | ₹25.00 | 2.77% |
| 2019-March | ₹20.00 | 3.20% |
| 2018-March | ₹20.00 | 3.60% |
| 2017-March | ₹20.00 | 4.81% |
Dr Reddys Laboratories Index Membership - Market Screener Classification
Screen DRREDDY by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Dr Reddys Laboratories Market Events Screener - Corporate Actions
Screen DRREDDY market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-21 | 2026-01-21 | Quarterly Result Announcement | NA | -1.00% |
| 2025-10-24 | 2025-10-24 | Quarterly Result Announcement | NA | -3.20% |
| 2025-07-24 | 2025-07-24 | Annual General Meeting | NA | 8.66% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -6.42% |
| 2025-07-10 | 2025-07-10 | Dividend | ₹ 8.00 /share | 10.57% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.30% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -3.53% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | -3.20% |
| 2024-10-28 | 2024-07-27 | Split | 1:5 | 0.00% |
| 2024-07-29 | 2024-07-29 | Annual General Meeting | NA | 9.51% |
| 2024-07-16 | 2024-07-17 | Dividend | ₹ 40.00 /share | 5.60% |
| 2023-07-11 | 2023-07-12 | Dividend | ₹ 40.00 /share | 4.71% |
| 2022-07-11 | 2022-07-13 | Dividend | ₹ 30.00 /share | 14.73% |
| 2021-07-09 | 2021-07-13 | Dividend | ₹ 25.00 /share | 3.54% |
Dr Reddys Laboratories Competitors Screener - Peer Comparison
Screen DRREDDY competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 411,966 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 169,103 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,075 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,432 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,571 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 95,722 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 91,849 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,653 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,517 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,085 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Dr Reddys Laboratories Company Announcements - News Screener
Screen DRREDDY latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | View |
| 2025-12-29 | Closure of Trading Window | View |
| 2025-12-29 | Board Meeting Intimation for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending On December 31 2025 | View |
| 2025-12-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-12 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-08 | Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 | View |
| 2025-12-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-26 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | View |
| 2025-11-26 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |